Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 5
Semaglutide and Heart-Failure Hemodynamics
A new case report describes semaglutide easing heart-failure pressures in one patient, but a single case can't prove a population-wide effect.
Semaglutide vs retatrutide: one vs three
Semaglutide hits one receptor and has cardiovascular outcome data. Retatrutide hits three and is still investigational.
Why Semax Comes as a Nasal Spray
Semax is a Russian-registered nasal-spray peptide with no FDA or EU approval. Here is what the intranasal evidence actually supports.
BMJ writers win MJA journalism awards
BMJ journalists won four 2026 MJA Awards for reporting on Mounjaro access, medical misogyny, and Trump-era health policy.
Do GLP-1 Drugs Raise Anemia Risk?
A 2026 review asks if semaglutide and tirzepatide quietly cause anemia through nutrient loss, finding a real signal but no proof of a direct cause.
GLP-1 drugs and hidradenitis suppurativa
A new review asks whether semaglutide and other GLP-1 drugs could help hidradenitis suppurativa. The evidence is early, and this is not an approved use.
Could GLP-1 drugs affect mitochondria?
A new hypothesis paper asks whether tirzepatide and other incretin drugs alter mitochondrial energy handling. It is not yet proven in humans.
Oral semaglutide 25 mg vs the injection
A Novo Nordisk funded indirect comparison put oral semaglutide 25 mg against the 2.4 mg injection. The weight-loss gap was about one percentage point.
Orforglipron liver safety: pooled data
A pooled analysis of 11,220 people across seven orforglipron phase 3 trials found no confirmed drug-induced liver injury. Here is what it checked, and did not.
PT-141 vs semaglutide: two brain targets
Both peptides act on brain receptors, and that is where the similarity stops. One is licensed for low sexual desire, the other for weight and heart risk.
What the EVOKE Alzheimer's trials found
In the EVOKE and EVOKE+ trials, oral semaglutide reduced Alzheimer's-linked biomarkers but did not slow cognitive or functional decline.
What predicts semaglutide weight loss?
A SELECT trial analysis of 7,594 patients found that baseline health measures barely predict semaglutide weight loss. Only sex and dose showed any link.